Psoriasis Redefined Webinar Series

The next innovation in skin has arrived.

A series of three CPD certified modules, presented by recognised experts in clinical psoriasis to support you should you decide to use BIMZELX® ▼ (bimekizumab) for treating your eligible adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.

Off

The BIMZELX®  Difference

paragraph-section-webinars
On

The BIMZELX®  Experience

paragraph-section-webinars
On

BIMZELX®  In Practice

On
Because we're in this together...

Report adverse events

Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk and hpra.ie/homepage/about-us/report-an-issue.

Adverse events should also be reported to UCB Pharma Ltd Email: UCBCares.UK@ucb.com and UCBCares.IE@ucb.com.

Feature requests

Help us to grow our resource the way you want it to grow.

Get in touch now

Date of preparation: October 2021
GB-P-BK-PSO-2100108